

115TH CONGRESS
2D SESSION

H. R. 5616

To require the National Institute of Minority Health and Health Disparities to submit to Congress a report on the impact of the opioid epidemic on minority communities.

IN THE HOUSE OF REPRESENTATIVES

APRIL 25, 2018

Ms. CLARKE of New York (for herself, Mr. RUSH, Mr. BUTTERFIELD, and Ms. KELLY of Illinois) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

A BILL

To require the National Institute of Minority Health and Health Disparities to submit to Congress a report on the impact of the opioid epidemic on minority communities.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Opioid Minority Health
5 Report to Congress Act of 2018”.

1 **SEC. 2. NATIONAL INSTITUTE OF MINORITY HEALTH AND**
2 **HEALTH DISPARITIES REPORT ON THE IM-**
3 **PACT OF THE OPIOID EPIDEMIC ON MINOR-**
4 **ITY COMMUNITIES.**

5 Not later than one year after the date of the enact-
6 ment of this Act, and annually thereafter, the National
7 Institute of Minority Health and Health Disparities shall
8 submit to the Committee on Finance of the Senate and
9 the Committees on Ways and Means and Energy and
10 Commerce of the House of Representatives, and make
11 public on the Internet website of Department of Health
12 and Human Services, a report on the impact of the opioid
13 epidemic on racial and ethnic minority groups (as defined
14 in section 1707(g) of the Public Health Service Act (42
15 U.S.C. 300u-6(g))), including the following:

16 (1) The scope of the epidemic within such racial
17 and ethnic minority groups with respect to the use
18 of prescription pain killers and illicit drug use, in-
19 cluding synthetics.

20 (2) The extent to which, and funding rec-
21 ommendations for how, the expansion of coverage
22 under the Medicare program under title XVIII of
23 the Social Security Act and the Medicaid program
24 under title XIX of such Act of medication-assisted
25 treatment and other treatment options could de-

1 crease the incidence of opioids use and of deaths
2 caused by opioids overdoses.

3 (3) The role of participation of such racial and
4 minority groups in clinical trials for pain manage-
5 ment therapy and alternatives to opioids pain man-
6 agement and recommendations on how to increase
7 such participation of such groups in such clinical
8 trials.

○